J P Morgan Chase & Co restated their neutral rating on shares of AstraZeneca plc (LON:AZN) in a research report released on Thursday morning.
A number of other research analysts also recently commented on the stock. BNP Paribas reissued a neutral rating and issued a GBX 5,300 ($66.14) price objective on shares of AstraZeneca plc in a research report on Wednesday. HSBC Holdings plc reaffirmed a hold rating and set a GBX 4,700 ($58.65) target price on shares of AstraZeneca plc in a report on Wednesday. Goldman Sachs Group, Inc. (The) reduced their target price on shares of AstraZeneca plc from GBX 4,000 ($49.92) to GBX 3,900 ($48.67) and set a sell rating for the company in a report on Tuesday. Deutsche Bank AG reaffirmed a buy rating and set a GBX 6,000 ($74.88) target price on shares of AstraZeneca plc in a report on Tuesday. Finally, Investec started coverage on shares of AstraZeneca plc in a report on Monday. They set a hold rating and a GBX 4,600 ($57.41) target price for the company. Four research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus target price of GBX 4,932.23 ($61.55).
Shares of AstraZeneca plc (LON:AZN) traded down 1.37% during mid-day trading on Thursday, reaching GBX 4239.00. 5,450,717 shares of the company’s stock traded hands. AstraZeneca plc has a 12 month low of GBX 3,680.00 and a 12 month high of GBX 5,505.00. The stock’s market cap is GBX 53.62 billion. The firm has a 50 day moving average price of GBX 4,399.74 and a 200-day moving average price of GBX 4,676.99.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.